Key result
Advances in 2019 highlighted the importance of lifetime cardiovascular risk assessment and the efficacy of novel targeted preventive therapies for patients with established ASCVD or diabetes.
This review summarizes key 2019 advances in cardiovascular prevention, highlighting the shift towards lifetime risk assessment, novel therapies for diabetes and dyslipidemia, and the impact of environmental and lifestyle factors.
Answers are grounded in this paper and cite their sources.
May guide updated prevention strategies; leaves open prospective validation of lifetime risk models and novel therapies.
While imaging is clearly important its use is likely to be useful after decades of exposure to risk factors and still provides assessment for short-to intermediate-term risk. Recently, a lifetime-perspective CardioVascular Disease (LIFE-CVD) model for the estimation of treatment-effects of cholesterol-lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people has been developed. This freely accessible online calculator (www.U-Prevent.com) estimates risk and treatment effects in terms of improved 10year risk, lifetime risk, and life-expectancy free of CVD and is designed to facilitate doctor-patient communication. Large trials of pharmacological intervention assessing outcomes over
No takes yet. Share an insight, caveat, or question.
Ray et al. (2020) conducted a review in Cardiovascular disease. Cardiovascular prevention strategies was evaluated. Advances in 2019 highlighted the importance of lifetime cardiovascular risk assessment and the efficacy of novel targeted preventive therapies for patients with established ASCVD or diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: